Current Cardiology Reports

, Volume 1, Issue 3, pp 192–198

The thienopyridines in coronary artery disease

  • Peter B. Berger


The thienopyridine class of antiplatelet drugs includes ticlopidine and clopidogrel, drugs that are used increasingly to prevent ischemic events in and out of the cardiac catheterization laboratory. Formerly, the only oral antiplatelet drug available for these purposes was aspirin, which has been studied randomized placebo-controlled trials in which 70,000 patients have been enrolled. Aspirin resulted in a 27% reduction in vascular death, myocardial infarction, and stroke in these trials. Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects. Both ticlopidine and clopidogrel have been compared with aspirin in randomized controlled trials and both are approximately 10% more effective than aspirin. Recently, ticlopidine and clopidogrel have been compared with one another; clopidogrel appears to be at least as efficacious as ticlopidine, but with few fewer side effects.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and recommended reading

  1. 1.
    Antiplatelet Trialist’s Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81–106.Google Scholar
  2. 2.
    Helgason CM, Tortorice KL, Winkler SR, et al.: Aspirin response and failure in cerebral infarction. Stroke. 1993, 24:345–350.PubMedGoogle Scholar
  3. 3.
    Helgason CM, Bolin KM, Hoff JA, et al.: Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994, 25:2331–2336.PubMedGoogle Scholar
  4. 4.
    Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397–403.PubMedCrossRefGoogle Scholar
  5. 5.
    Buchanan MR, Brister SJ: Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995, 11:221–227.PubMedGoogle Scholar
  6. 6.
    Coukell AJ, Markham A: Clopidogrel. Drugs. 1997, 54:745–750.PubMedCrossRefGoogle Scholar
  7. 7.
    Savi P, Herbert JM: ADP receptors on platelets and ADP-selective antiaggregating agents. Med Res Rev. 1996, 16:159–179.PubMedCrossRefGoogle Scholar
  8. 8.
    Mills DC, Puri R, Hu CJ, et al.: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992, 12:430–436.PubMedGoogle Scholar
  9. 9.
    Yang LH, Fareed J: Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res. 1997, 86:479–491.PubMedCrossRefGoogle Scholar
  10. 10.
    Puri RN, Colman RW: ADP-induced platelet activation. Crit Rev biochem molec biol. 1997, 3:437–502.Google Scholar
  11. 11.
    Balsano F, Rizzon P, Violi F, et al.: Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation. 1990, 82:17–26.PubMedGoogle Scholar
  12. 12.
    Bertrand ME, Allain H, Lablanche JM: Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study. Circulation 1990, 82:111–190.Google Scholar
  13. 13.
    White CW: Antiplatelet agents are effective in reducing the immediate complications of PTCA: Results from the ticlopidine multicenter trial. Circulation. 1987, 76 (Suppl IV):IV-400.Google Scholar
  14. 14.
    Berger PB, Dzavik V, Al-Rashdan I, et al.: Does Ticlopidine Reduce Reocclusion After Successful Balloon Angioplasty of Coronary Occlusions? Insights from TOSCA [abstract]. J Am Coll Cardiol. 1999, 33:40A.Google Scholar
  15. 15.
    Morice M-C, Lefevre T, Grines CL, et al.: Antiplatelet treatment with ticlopidine and aspirin does not prevent major adverse cardias events in acute myocardial infarction patients treated with balloon angioplasty alone. Circulation. 1998, 98(Suppl I):I-572A.Google Scholar
  16. 16.
    Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study. New Engl J Med. 1998, 339:1665–1671.PubMedCrossRefGoogle Scholar
  17. 17.
    Schomig A, Neumann FJ, Kastrati A, et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl J Med. 1996, 334:1084–1089.PubMedCrossRefGoogle Scholar
  18. 18.
    Hall P, Nakamura S, Maiello L, et al.: A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996, 93:215–222.PubMedGoogle Scholar
  19. 19.
    Urban P, Macaya C, Rupprecht HJ, et al.: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998, 98:2126–2132.PubMedGoogle Scholar
  20. 20.
    Bertrand ME, Legrand V, Boland J, et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998, 98:1597–1603.PubMedGoogle Scholar
  21. 21.
    Rupprecht HJ, Darius H, Borkowski U, et al.: Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 1998, 97:1046–1052.PubMedGoogle Scholar
  22. 22.
    Wilson S, Rihal CS, Bell MR, et al.: Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol. 1999, 83:1006–1011.PubMedCrossRefGoogle Scholar
  23. 23.
    Schomig A, Kastrati A, Shuhlen H, et al.: Risk factor analysis for stent occlusion within the first month after successful coronary stent placement. J Am Coll Cardiol. 1998, 31(Suppl A):99A.CrossRefGoogle Scholar
  24. 24.
    Steinhubl SR, Lauer MS, Mukherjee DP, et al.: The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998, 32:1366–1370.PubMedCrossRefGoogle Scholar
  25. 25.
    Steinhubl SR, Bulog C, Topol EJ: Pretreatment with ticlopidine prior to stenting is associated with a substantial decrease in complications: data from the EPISTENT trial [abstract]. Circulation. 1998, 98(Suppl I):I-573.Google Scholar
  26. 26.
    The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998, 352:87–92.CrossRefGoogle Scholar

The first study to indicate that the risk of late stent thrombosis when ticlopidine is discontinued 2 weeks after stent placement is less than the risk of severe hematologic side effects from ticlopidine when it is continued for 4 weeks

  1. 27.
    • Steinhubl SR, Tan WA, Foody JM, et al.: Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA. 1999, 281:806–810.PubMedCrossRefGoogle Scholar
  2. 28.
    Berger PB, Bell MR, Grill DE, et al.: Safety and efficacy of ticlopidine for only two weeks after successful intracoronary stent placement. Circulation. 1999, 99:248–253.PubMedGoogle Scholar
  3. 29.
    Boneu B, Destelle G: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost. 1996, 76:939–943.PubMedGoogle Scholar
  4. 30.
    The CAPRIE Investigators: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996, 348:1329–1339.CrossRefGoogle Scholar
  5. 31.
    Easton JD: Net benefit of clopidogrel over aspirin for the prevention of atherothrombotic events. Cerebrovasc Dis. 1998, 8(suppl 4):46.Google Scholar
  6. 32.
    Gibbons RJ, Chatterjee K, Daley J, et al.: ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation. 1999, 99:2829–2848.PubMedGoogle Scholar
  7. 33.
    Bachmann F, Savcic M, Hauert J, et al.: Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J. 1996, Suppl 263A.Google Scholar
  8. 34.
    • Wang X, Oetgen M, Maida R, et al.: The effectiveness of the combination of Plavix and aspirin versus Ticlid and aspirin after coronary stent implantation. J Am Coll Cardiol. 1999, 33:13A. This study suggested that clopidogrel is as effective as ticlopidine among patients receiving coronary stents, and better tolerated.Google Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Peter B. Berger
    • 1
  1. 1.Division of Cardiovascular Diseases-W16Mayo ClinicRochesterUSA

Personalised recommendations